FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1310-1312 March 23, 2006 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Cohen, J. C. PubMed Citation

Just when we thought we understood everything about low-density lipoprotein (LDL) cholesterol and its relationship to cardiovascular risk, along comes a discovery that reveals a new control mechanism and suggests a strategy for the prevention of atherosclerotic cardiovascular disease.

Plasma levels of LDL cholesterol are in large part determined by the activity of LDL receptors in the liver. Autosomal dominant familial hypercholesterolemia — with its high levels of LDL cholesterol, xanthomas, and premature atherosclerosis — is caused by mutations either in the gene encoding the LDL receptor or in the gene encoding apolipoprotein B — the protein in LDL cholesterol . . . [Full Text of this Article]

Source Information

Dr. Tall is a professor of medicine and physiology and the director of the Specialized Center of Research in Molecular Medicine and Atherosclerosis at the Columbia University Medical Center, New York.

This article has been cited by other articles:

• Graham, M. J., Lemonidis, K. M., Whipple, C. P., Subramaniam, A., Monia, B. P., Crooke, S. T., Crooke, R. M. (2007). Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 48: 763-767 [Abstract] [Full Text]  
• (2006). Variations in Low-LDL Gene Linked with Reduced CHD Risk. Journal Watch Cardiology 2006: 3-3 [Full Text]